THD NewsDesk, New Delhi: On the 5th August 2020, Lupin pharmaceuticals launched the Favipiravir drug with the name of “Covihalt” for the treatment of patients with slight to notable symptoms of COVID-19 at Rs. 49 per tablet in India.
Covihalt has been authorized by the DGGI (Drug Controller General of India) for urgent and emergency use, as reported in a regulatory filing by Lupin.
Rajeev Sibal, the president of Lupin (India Region Formulations) said, “the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.”
The impacts of the ongoing COVID-19 pandemic have been sensed by people from all walks of life. The situation has not only grown grave in the context of public health and well-being, but the virus has entered and devastated several other expanses of life. The financial and monitory onus has left the impoverished penniless, vulnerable, and helpless.
Other contributors like unemployment and inflation have added to the cost of the treatment and medication for COVID-19 patients.
Many Indian indigenous Biotechnological and pharmaceutical groups are hence attempting to devise cost-effective treatment and medicinal drugs to enhance the accessibility and approachability for it to be in everybody’s reach.
The aim of the development of, “Covihalt” is to make it available at a pocket-friendly price so that it can be accessed by people from all classes and financial backgrounds.
The drug is made available as 200 mg tablets in the form of tablets (strips of 10), costing Rs. 49 per tablet. The intensity of the pill has been developed considering the ease of the administration and is a relatively mild tablet.
Lupin has attained considerable profits as its shares traded at Rs. 943.70 apiece, which is 0.32% higher on BSE.
With the introduction of the drug named, “Covihalt” launched by Lupin pharmaceuticals, the treatment for COVID-19 might become more affordable and pocket-friendly.
